An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease.

Trial Profile

An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2013

At a glance

  • Drugs MEDI 6012 (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Coronary artery disease
  • Focus Adverse reactions
  • Sponsors AlphaCore Pharma
  • Most Recent Events

    • 09 Oct 2012 Results have been reported in an AlphaCore Pharma media release.
    • 09 Oct 2012 Primary safety endpoints have been met, according to an AlphaCore media release.
    • 09 Oct 2012 Status changed from recruiting to completed, based on an AlphaCore Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top